The clinical trial’s objective is to estimate the survival rate of patients 34 months after randomization, estimate the proportion of patients without progression 34 months after randomization, evaluate quality of life and the influence on the pain scale scoring using the standardized EORTC QLQ-C30 (version 3.0) questionnaire and the incidence of adverse events. An exploratory objective is to search for potential biomarkers that could play a role as prognostic factors, indicate the biological effect of ACI on the immune-reponse or identify a subgroup of patients profiting from cancer immunotherapy based on gene expression profiling.